lm-108
mAbexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2022 (NCT05199753)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1ANTAGONIST
PDCD1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06825494 | Phase 1/Phase 2 (Phase 2) | Apr 8, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06873854 | Phase 2 | Mar 26, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, LaNova Medicines Limited |
| NCT06821503 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06620822 | Phase 2 | Sep 30, 2024 | Huazhong University of Science and Technology |
| NCT06387628 | Phase 2 | Jul 10, 2024 | Fudan University |
| NCT06479759 | Phase 2 | Jan 12, 2024 | Huazhong University of Science and Technology |
| NCT05518045 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2022 | LaNova Medicines Limited, Peking University |
| NCT05255484 | Phase 1/Phase 2 (Phase 2) | May 26, 2022 | LaNova Medicines Limited |
| NCT05199753 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2022 | LaNova Medicines Limited |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LaNova Medicines Limited | For profit | 4 | 4 | 1 | 2022 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 3 | 2 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1